Decision Resources, Inc., one of the world's leading research and advisory firms for pharmaceutical and health care issues, finds that the revolution that occurred in the United States to treat advanced renal cell carcinoma because of the introduction of Bayer/Onyx's Nexavar (sorafenib) and Pfizer's Sutent (sunitinib) will be mirrored in Europe and Japan following the launch of these drugs in those markets.

The new Pharmacor report entitled Renal Cell Carcinoma finds that Nexavar and Sutent have revolutionized the treatment of advanced renal cell carcinoma by supplanting the only therapeutic option that had been available as of 2005, cytokine immunotherapy, a class of drugs long considered unsatisfactory by both patients and physicians due to severe toxicities and limited efficacy. The report also finds that Roche/Genentech's Avastin (bevacizumab) and Wyeth's temsirolimus will play significant roles in the future market to treat renal cell carcinoma.

"Sales of the vascular endothelial growth factor inhibitors Nexavar, Sutent and Avastin will be approximately $500 million each in 2015, and potential exists for significantly higher sales if the drugs are used in combination," said Mohamed Muhsin, analyst at Decision Resources, Inc. "The rapid development of these drugs over the past three years suggests that Bayer/Onyx, Pfizer, and Roche/Genentech anticipated the commercial rewards of addressing the unmet needs in this market caused by the shortcomings of cytokine immunotherapy."

About Renal Cell Carcinoma

Renal cell carcinoma accounts for 85% of all kidney cancers. In the United States, approximately 30,000 incident cases are diagnosed each year, accounting for 3% of all cancer cases and approximately 1.5% of cancer deaths.

About Decision Resources

Decision Resources, Inc. ( is a world leader in market research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

  For more information, contact:    Elizabeth Marshall   Decision Resources, Inc.   781-296-2563 

SOURCE: Decision Resources, Inc.

CONTACT: Elizabeth Marshall of Decision Resources, Inc.,

TennCare RFP Seeks Middle Tennessee MCO

View Now